Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Multiparameter flow cytometry in the evaluation of myelodysplasia : Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Porwit, Anna LU ; Béné, Marie C. ; Duetz, Carolien ; Matarraz, Sergio ; Oelschlaegel, Uta ; Westers, Theresia M. ; Wagner-Ballon, Orianne ; Kordasti, Shahram ; Valent, Peter and Preijers, Frank , et al. (2023) In Cytometry Part B - Clinical Cytometry 104(1). p.27-50
Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic... (More)

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
consensus, ELN, flow cytometry, myelodysplastic syndromes, standardization
in
Cytometry Part B - Clinical Cytometry
volume
104
issue
1
pages
27 - 50
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:36537621
  • scopus:85144283609
ISSN
1552-4949
DOI
10.1002/cyto.b.22108
language
English
LU publication?
yes
id
c05e54a8-1313-433c-b3ba-f9538abc0b1a
date added to LUP
2023-01-23 15:03:27
date last changed
2024-04-16 12:41:40
@article{c05e54a8-1313-433c-b3ba-f9538abc0b1a,
  abstract     = {{<p>Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34<sup>+</sup>CD19<sup>−</sup>) count &gt;3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.</p>}},
  author       = {{Porwit, Anna and Béné, Marie C. and Duetz, Carolien and Matarraz, Sergio and Oelschlaegel, Uta and Westers, Theresia M. and Wagner-Ballon, Orianne and Kordasti, Shahram and Valent, Peter and Preijers, Frank and Alhan, Canan and Bellos, Frauke and Bettelheim, Peter and Burbury, Kate and Chapuis, Nicolas and Cremers, Eline and Della Porta, Matteo G. and Dunlop, Alan and Eidenschink-Brodersen, Lisa and Font, Patricia and Fontenay, Michaela and Hobo, Willemijn and Ireland, Robin and Johansson, Ulrika and Loken, Michael R. and Ogata, Kiyoyuki and Orfao, Alberto and Psarra, Katherina and Saft, Leonie and Subira, Dolores and te Marvelde, Jeroen and Wells, Denise A. and van der Velden, Vincent H.J. and Kern, Wolfgang and van de Loosdrecht, Arjan A.}},
  issn         = {{1552-4949}},
  keywords     = {{consensus; ELN; flow cytometry; myelodysplastic syndromes; standardization}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{27--50}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Cytometry Part B - Clinical Cytometry}},
  title        = {{Multiparameter flow cytometry in the evaluation of myelodysplasia : Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group}},
  url          = {{http://dx.doi.org/10.1002/cyto.b.22108}},
  doi          = {{10.1002/cyto.b.22108}},
  volume       = {{104}},
  year         = {{2023}},
}